SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio Technology General - BTGC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: yosi s who wrote (1857)6/19/1999 12:07:00 PM
From: Jim Oravetz  Read Replies (1) of 2028
 
yosi
1)yes, non healing wounds is a large target for Oxan. Certainly, BTGC is moving aggressively to expand Oxan. sales in this area. However, if this solution becomes too lucrative, this will almost certainly become a signal for generic co's. BTGC will get most of the initial profits but it may not last too long.
2)The Jap. companies will not significantly contribute $$ for several quarters. A year from now, it will be better.
3)Hep-B is not a HUGE profit drug. It will contribute, but not all that much (to propel the stock upward).

IMHO,
Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News